Apellis Pharmaceuticals (NASDAQ:APLS), traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.
The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders. In addition to its ophthalmology programs, Apellis is advancing clinical candidates in hematology, including indications such as paroxysmal nocturnal hemoglobinuria (PNH), and in rare kidney diseases like C3 glomerulopathy. Its diversified pipeline reflects a strategy to address high-unmet-need populations across multiple therapeutic areas.
Founded in 2003 and headquartered in Waltham, Massachusetts, Apellis operates with a global footprint, conducting clinical trials and engaging regulatory authorities in key markets including the United States, Europe and Asia. The company collaborates with research institutions and industry partners to enhance its discovery engine and advance its development candidates from preclinical studies through late-stage trials.
Apellis is led by President and Chief Executive Officer Cedric Francois, who brings extensive experience in biotechnology and drug development. Under his leadership, the company continues to expand its scientific capabilities and pursue strategic initiatives aimed at delivering transformative therapies to patients worldwide.
